Skip to main content
. Author manuscript; available in PMC: 2010 Sep 7.
Published in final edited form as: RNA Biol. 2009 Sep 24;6(4):426–433. doi: 10.4161/rna.6.4.8841

Table 3.

Top aberrantly expressed RBPs in tumor

Number of tissues with aberrant expression RBPS
4 FUBP1, NCBP2, DKC1*, NONO*, EIF3S9*
3 CPSF6*, FXR1, PTBP1, STRBP, SYNJ2, SIAHBP1, RPL18, CSTF2, MRPL23, PNPT1, MARS, GARS, DSRAD, ANKRD17, LA*, C20orf119*, HNRPUL1*, NOL8*, NPM1*, PAIAP1*, RBM28*, RO60*, TACC1**
2 SNRPA, RBM8A, SLBP, RBM35A, RPS5*, RTCD1, HNRPG, RPL7, RBM14, FUS, RBM26, FUBP2, TRBP2, PPIE, CSTF3, RBM9, PSMA1, AKAP1, APOBEC1, NUFIP1, PABP4, RBM10, EIF3S4, TUT1, TIA1, RBM25**, IREB1**, NKRF

The results obtained for each tumor type by the combined SAGE and microarray analyses were pulled together to determine RBPs that are aberrantly expressed in multiple tumor types. The genes labeled with *were determined to be upregulated in three different types of brain tumors and the genes labeled with **were determined to be downregulated in tumor samples.